• Loading stock data...
Est. 2004

Thursday 02/21/2019

We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.


Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More


  • 11:41 AM

    BATON ROUGE, LA– OBMP, (Marketwired – December 12, 2016) – OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) (“OncBioMune” or the “Company”), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, today announces that the European Patent Office has approved the Company’s patent application number 12701292.0 protecting ProscaVax as a PSA (prostate specific antigen) cancer vaccine. The patent is broad in scope covering an array of therapeutic cancer vaccine compositions built upon OncBioMune’s protein

    Read more
  • 4:10 PM

    ATLANTA, GA–(Marketwired – Nov 7, 2016) – GeoVax Labs, Inc. (OTCQB: GOVX) announced today its collaboration with ViaMune, Inc. for the co-development of each company’s cancer immunotherapy programs. Both companies’ products target an abnormal form of the autologous cell surface-associated protein, Mucin 1 (MUC1), which is over-expressed in the majority of known tumor types. Due to overexpression and/or aberrant glycosylation of MUC1, this “tumor-associated antigen” (TAA) is often recognized as abnormal by patients’ immune system but is not sufficiently immunogenic

    Read more
  • 2:30 PM

    MONMOUTH JUNCTION, N.J., July 1, 2016, CTSO, /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood purification cartridge to prevent or treat deadly inflammation and organ failure in critically-ill and cardiac surgery patients around the world, announced that it has closed upon a $10 million senior debt facility with the Life Sciences Group of Bridge Bank, a division of Western Alliance Bank (NYSE: WAL). CytoSorbents Corporation and its U.S. operating subsidiary, CytoSorbents Medical,

    Read more
  • 2:17 PM

    MONMOUTH JUNCTION, N.J., June 22, 2016, CTSO, /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in critical care immunotherapy specializing in blood purification, announced that it was awarded a $150,000 Phase I Small Business Technology Transfer (STTR) contract to develop blood purification technologies that may enable universal plasma. A successful Phase I effort will position the company to be competitive for selection in the Phase II STTR program, valued at more than $1 million. Dr. Phillip Chan, MD, PhD, Chief

    Read more
  • 2:35 PM

    ORLANDO, Fla., May 19, 2016, IMUN, /PRNewswire/ — Immune Therapeutics, Inc. (OTCQB: IMUN ), a clinical-stage biotech company providing immunotherapy solutions for the treatment of infectious and non-infectious diseases, such as HIV/AIDS and cancer, with a focus on emerging nations, today announced its attendance at the 69th World Health Assembly ( ” WHA ” ) in Geneva, Switzerland to promote LodonalTM. The WHA is the decision-making body of the World Health Organization (“WHO”). It is attended by delegations from all WHO member

    Read more
  • 2:00 PM

    ORLANDO, FL– IMUN, (Marketwired – Apr 21, 2016) – Immune Therapeutics Inc. (OTCQB: IMUN) today announced that they have signed a binding Letter of Intent to acquire Chinese Chimeric Super Antigen Receptor T cell (CAR-T) cocktail therapy, Immuno-Oncology patents (pending), manufacturing technology, and clinical data of the aforementioned therapies from Super-T Cell Cancer Company (“STCC”) a newly formed corporation. “This CAR-T cell technology licensing further accelerates IMUN’s growth in the Immuno-Oncology field as we evaluate paths to commercialization both in

    Read more
Public Wire Banner